GlobeNewsWire
24 Sept 2026, 11:50 UTC · 1h ago
Verdict
Headline takes no side. We score NXTS +0.40 across two claims — moderately bullish.
+0.40moderately bullish
More positive than 64% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Nexentis announced that Prof. Dan T. Major has joined the Scientific Advisory Board of its subsidiary, MitoCareX.
Newpress release dated Sept. 24, 2026
So whatAdding academic expertise in in silico modeling aims to accelerate the prioritization of discovery programs by next year.
More positive than 42% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
MitoCareX is expanding its internal computational drug discovery capabilities and evaluating methods for program prioritization.
Newpress release dated Sept. 24, 2026
So whatIncreased internal capacity reduces long-term reliance on third-party consultants, potentially improving R&D margins.
Near neutral — 98% of claims this week are stronger
Which stocks this story touches
More positive than 64% of ticker scores this week
The company is strengthening its drug discovery capabilities through the appointment of a leading computational chemistry expert to its subsidiary's advisory board.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
32m ago
—
NXTS hasn't traded since this ran. Last close $1.46 (Sep 23); the reaction starts at the next open.
NXTS chart →
